Noteworthy, MAGE-3 was highly expressed by MM cells; this finding suggests that MAGE-3, an extensively utilised therapeutic target for cancer immunotherapy (Marchand et al, 1999; Nishiyama et al, 2001), represents a promising candidate for CTA-based immunotherapy in the majority of MM patients. This evidence concerns the gene MAGEA3 and Miyoshi myopathy.